Completed PHASE2 INTERVENTIONAL 1-arm NCT03113110

Empagliflozin in Post-Transplantation Diabetes Mellitus (EMPTRA-DM)

Sponsor: Medical University of Vienna

Conditions Posttransplant Diabetes Mellitus

Updated 5 times since 2017 Last updated: May 3, 2019 Started: Jan 15, 2017 Primary completion: Jun 13, 2017 Completion: May 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Posttransplant Diabetes Mellitus, this trial is completed. The trial is conducted by Medical University of Vienna and has accumulated 5 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
May 2017 — Jun 2019 [monthly]

Recruiting PHASE2

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria